{
    "clinical_study": {
        "@rank": "164768", 
        "arm_group": {
            "arm_group_label": "Dose Finding Phase", 
            "arm_group_type": "Experimental", 
            "description": "This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose of Belinostat when administered in combination with CHOP. In Part A of the study, up to three sequential dose cohorts will enroll a maximum of 6 patients each.\nEnrollment will begin with the enrollment of patients into Cohort 3.\nOn Day 1 of each 21-day treatment cycle, the study treatment will start with belinostat followed by CHOP regimen."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for\n      belinostat when combined with CHOP regimen and establish the recommended belinostat dose for\n      the Phase 3 study."
        }, 
        "brief_title": "Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral T-cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Peripheral"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to\n      evaluate the Maximum Tolerated Dose (MTD) of belinostat when administered in combination\n      with CHOP."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 years or above\n\n          -  Life Expectancy > 3 months\n\n          -  Histologically confirmed diagnosis of PTCL\n\n          -  Patients with transformed CTCL eligible for CHOP regimen\n\n          -  Measurable disease based on Cheson 2007 criteria\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status < 2\n\n        Exclusion Criteria:\n\n          -  Known active Hepatitis B/ Hepatitis C/ HIV infection\n\n          -  Known, uncontrolled CNS metastases or primary CNS lymphoma\n\n          -  Deep vein thrombosis diagnosed within 3 months\n\n          -  Ongoing treatment for pre-existing cardiovascular disease\n\n          -  Neuropathy Grade 3 or more\n\n          -  Previous extensive radiotherapy except limited field RT for locally advanced   nasal\n             NK PTCL or for pain palliation\n\n          -  Prior therapy with severely myelotoxic regimens, including autologous and\n             allogenic stem cell transplantation\n\n          -  Prior therapy with HDAC inhibitors (except for CTCL)\n\n          -  Inadequate hematological, hepatic, or renal function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839097", 
            "org_study_id": "SPI-BEL-12-104"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dose Finding Phase", 
                "description": "Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:\nCohort 1: belinostat 1000 mg/m2 IV on Day 1\nCohort 2: belinostat 1000 mg/m2 IV on Day 1-2\nCohort 3: belinostat 1000 mg/m2 IV on Day 1-3\nCohort 4: belinostat 1000 mg/m2 IV on Day 1-4\nCohort 5: belinostat 1000 mg/m2 IV on Day 1-5", 
                "intervention_name": "Belinostat", 
                "intervention_type": "Drug", 
                "other_name": "PXD101"
            }, 
            {
                "arm_group_label": "Dose Finding Phase", 
                "description": "Cyclophosphamide - 750 mg/m2 - IV - Day 1\nVincristine - 1.4 mg/m2 - IV - Day 1\nDoxorubicin - 50mg/m2 - IV - Day 1\nPrednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat.", 
                "intervention_name": "CHOP", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cyclophosphamide", 
                    "Vincristine", 
                    "Doxorubicin", 
                    "Prednisone"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Doxorubicin", 
                "Prednisone", 
                "Vincristine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "PTCL", 
            "Maximum Tolerated Dose", 
            "Belinostat"
        ], 
        "lastchanged_date": "January 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "bhamby@uab.edu", 
                    "last_name": "Brittany Hamby, RN, BSN, OCN", 
                    "phone": "205-934-0314"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmngham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama, Birmingham"
                }, 
                "investigator": {
                    "last_name": "Naresh Bellam, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jhodgson@negacancer.com", 
                    "last_name": "Jamie Hodgson, CCRC", 
                    "phone": "706-353-2990"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30607"
                    }, 
                    "name": "Northeast Georgia Cancer Care, LLC"
                }, 
                "investigator": {
                    "last_name": "Petros Nikolinakos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Amundson.michelle@mayo.edu", 
                    "last_name": "Michelle Amundson", 
                    "phone": "507-293-1933"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Patrick B Johnston, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "salarson@dom.wustl.edu", 
                    "last_name": "Sarah Larson", 
                    "phone": "314-362-3257"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Amanda Cashen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "MValentinetti@HackensackUMC.org", 
                    "last_name": "Marisa Valentinetti, RN", 
                    "phone": "551-996-5900"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "John Theurer Cancer Center at Hackensack University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Tatyana Feldman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mmackenzie@hoannj.com", 
                    "last_name": "Michelle Mackenzie, RN", 
                    "phone": "973-538-3593"
                }, 
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07962"
                    }, 
                    "name": "Hematology - Oncology Associates of Northern NJ P.A"
                }, 
                "investigator": {
                    "last_name": "Charles M Farber, Md, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Dw2316@columbia.edu", 
                    "last_name": "Danielle Wright", 
                    "phone": "212-326-5731"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10019"
                    }, 
                    "name": "Columbia University Medical Center/Center for Lymphiod Malignancies"
                }, 
                "investigator": {
                    "last_name": "Jasmine Zain, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Peggy.alton@duke.edu", 
                    "last_name": "Peggy Alton", 
                    "phone": "919-681-4769"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Anne Beaven, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)", 
        "overall_contact": {
            "email": "william.le@sppirx.com", 
            "last_name": "William Le", 
            "phone": "214-504-1938"
        }, 
        "overall_official": {
            "affiliation": "Spectrum Pharmaceuticals, Inc", 
            "last_name": "Mi Rim Choi, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the MTD for belinostat when combined with CHOP regimen and establish the Phase 3 recommended belinostat dose.", 
            "measure": "Maximum Tolerated Dose (MTD)", 
            "safety_issue": "Yes", 
            "time_frame": "up to 5 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839097"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess safety and tolerance of belinostat when given in combination with CHOP regimen. Safety and tolerance will be mainly characterized by the number and severity of treatment emergent adverse events, and treatment related AEs that occur or worsen after the first dose of study treatment.", 
                "measure": "Safety and tolerance", 
                "safety_issue": "Yes", 
                "time_frame": "up to 5 days"
            }, 
            {
                "description": "Overall response rate (ORR) after 6 cycles of BelCHOP regimen", 
                "measure": "Overall Response Rate", 
                "safety_issue": "Yes", 
                "time_frame": "126 days"
            }, 
            {
                "description": "Pharmacokinetics of belinostat when co-administered with CHOP regimen. The concentration of Belinostat to assess the effectiveness.", 
                "measure": "Effectiveness of study drug", 
                "safety_issue": "Yes", 
                "time_frame": "126 days"
            }
        ], 
        "source": "Spectrum Pharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spectrum Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}